The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Paclitaxel (Taxol)
Abstract
The taxanes are an important new class of anticancer agents that exert their cytotoxic effects through a unique mechanism. Paclitaxel (Taxol), the first taxane in clinical trials, is active against a broad range of cancers that are generally considered to be refractory to conventional chemotherapy. This has led to the regulatory approval of paclitaxel in the United States and many other countries for use in the palliative therapy of patients with ovarian and breast cancers resistant to chemotherapy. The challenge now is to develop strategies using paclitaxel in the initial therapy of cancers in which cure or improved survival may . . .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TTFields are similar to the morphological abnormalities seen in cells treated with agents that interfere directly (18,19) or indirectly (20 -22) with microtubule polymerization (e.g., Taxol).”
From Disruption of cancer cell replication by alternating electric fields (2004) · cites this paper as [19]
Citations
Cites
Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., & McPhail, A. T. (1971) · Journal of the American Chemical Society · doi:10.1021/ja00738a045 · Cited by 4,073
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
Taxol stabilizes microtubules in mouse fibroblast cells.
Schiff, P. B., & Horwitz, S. B. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1561 · Cited by 1,970
Hypersensitivity reactions from taxol.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1263 · Cited by 1,174
Self-citationMcGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., Grumbine, F. C., Ettinger, D. S., Armstrong, D. K., & Donehower, R. C. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-4-273 · Cited by 1,100
Self-citationNicolaou, K. C., Yang, Z., Liu, J. J., Ueno, H., Nantermet, P. G., Guy, R. K., Claiborne, C. F., Renaud, J., Couladouros, E. A., Paulvannan, K., et al. (1994) · Nature · doi:10.1038/367630a0 · Cited by 1,096
Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations.
Jordan, M. A., Toso, R. J., Thrower, D., & Wilson, L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9552 · Cited by 1,095
Taxol: A Novel Investigational Antimicrotubule Agent
Rowinsky, E. K., Cazenave, L. A., & Donehower, R. C. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.15.1247 · Cited by 1,090
Self-citationPhase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer
Holmes, F. A., Walters, R. S., Theriault, R. L., Buzdar, A. U., Frye, D. K., Hortobagyi, G. N., Forman, A. D., Newton, L. K., & Raber, M. N. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797-a · Cited by 746
Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol
Ringel, I., & Horwitz, S. B. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.4.288 · Cited by 677
Research works printed but not linked: 47
- Burkhart CA, 1994, Cancer Res, 54, 5779
- Rowinsky EK, 1988, Cancer Res, 48, 4093
- Roberts JR, 1990, Cancer Res, 50, 710
- Rowinsky EK, 1989, Cancer Res, 49, 4640
- Tishler RB, 1992, Cancer Res, 52, 3495
- Horwitz SB, 1993, Monogr Natl Cancer Inst, 15, 55
- Grem JL, 1987, Cancer Treat Rep, 71, 1179
- Kris MG, 1986, Cancer Treat Rep, 70, 605
- Donehower RC, 1987, Cancer Treat Rep, 71, 1171
- Wiernik PH, 1987, Cancer Res, 47, 2486
- Ohnuma T, 1985, Proc Am Assoc Cancer Res, 26, 167
- Rowinsky EK, 1993, Semin Oncol, 20, 1
- Adams JD, 1993, Monogr Natl Cancer Inst, 15, 141
- Lassus M, 1985, Proc Am Soc Clin Oncol, 4, 268
- Rowinsky EK, 1993, Monogr Natl Cancer Inst, 15, 107
- Arbuck SG, 1993, Monogr Natl Cancer Inst, 15, 117
- Gianni L, 1994, Proc Am Soc Clin Oncol, 13, 74
- Kennedy MJ, 1994, Proc Am Soc Clin Oncol, 13, 137
- Longnecker SM, 1987, Cancer Treat Rep, 71, 53
- Rowinsky EK, 1993, Semin Oncol, 20, 16
- Schilder LE, 1994, Proc Am Soc Clin Oncol, 13, 136
- Monsarrat B, 1990, Drug Metab Dispos Biol Fate Chem, 18, 895
- Monsarrat B, 1993, Monogr Natl Cancer Inst, 15, 39
- Cresteil T, 1994, Cancer Res, 54, 386
- Harris JW, 1994, Cancer Res, 15, 4026
- Venook AP, 1994, Proc Am Soc Clin Oncol, 13, 139
- LeBlanc GA, 1992, Cancer Res, 52, 540
- McGuire WP, 1993, Proc Am Soc Clin Oncol, 12, 255
- Holmes FA, 1994, Ann Oncol, 5, 197
- Wiltshaw E, 1979, Cancer Treat Rep, 63, 1545
- McGuire WP. Paclitaxel in the treatment of ovarian cancer. In: Proceedings of the 30th Annual Meeting of the American Society of Clinical Oncology, Dallas, May 14–17, 1994. American Society of Clinical Oncology Educational Book. Chicago: American Society of Clinical Oncology, 1994:204-13.
- Seidman A, 1993, Proc Am Soc Clin Oncol, 12, 63
- Gelmon K, 1994, Ann Oncol, 5, 198
- Holmes FA, 1993, Proc Am Soc Clin Oncol, 12, 94
- Hudis C, 1994, Proc Am Soc Clin Oncol, 13, 65
- Ettinger DS, 1993, Proc Am Soc Clin Oncol, 12, 329
- Kirschling RJ, 1994, Proc Am Soc Clin Oncol, 13, 326
- Forastiere AA, 1993, Monogr Natl Cancer Inst, 15, 181
- 10.1002/1097-0142(19900601)65:11<2478::aid-cncr2820651114>3.0.co;2-s · DOI · Paper page
- 10.1002/1097-0142(19931015)72:8<2457::aid-cncr2820720825>3.0.co;2-z · doi:10.1002/1097-0142(19931015)72:8<2457::aid-cncr2820720825>3.0.co;2-z
- Einzig AI, 1993, Proc Am Soc Clin Oncol, 12, 194
- Brown T, 1993, Proc Am Soc Clin Oncol, 13, 200
- Rowinsky EK, 1992, Semin Oncol, 19, 646
- Roth BJ, 1994, Proc Am Soc Clin Oncol, 13, 230
- Bissery MC, 1991, Cancer Res, 51, 4845
- Trudeau ME, 1993, Proc Am Soc Clin Oncol, 12, 64
- De Forni M, 1994, Ann Oncol, 5, 202
Cited by
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Cannistra, S. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041842 · Cited by 2,129
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00947-7 · Cited by 1,643
Nanomedicine—Challenge and Perspectives
Riehemann, K., Schneider, S. W., Luger, T. A., Godin, B., Ferrari, M., & Fuchs, H. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802585 · Cited by 1,305
Barua, S., & Mitragotri, S. (2014) · Nano Today · doi:10.1016/j.nantod.2014.04.008 · Cited by 1,257
Metadata
- Authors
- Rowinsky, E. K., & Donehower, R. C.
- Affiliations
- Johns Hopkins University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1995-04-13
- Volume
- 332
- Issue
- 15
- Pages
- 1004-1014
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4255762755
- Cited by
- 1,924
- References
- 74
- Citations by year
- 2026: 52 · 2025: 65 · 2024: 50 · 2023: 57 · 2022: 65 · 2021: 75 · 2020: 99 · 2019: 66 · 2018: 52 · 2017: 60 · 2016: 70 · 2015: 77 · 2014: 65 · 2013: 68 · 2012: 72
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- paclitaxel, taxanes, anticancer agents, cytotoxicity mechanism, ovarian cancer, breast cancer, palliative care
- MeSH terms
- Arrhythmias, Cardiac, Breast Neoplasms, Drug Hypersensitivity, Female, Humans, Ovarian Neoplasms, Peripheral Nervous System Diseases, Paclitaxel
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Paclitaxel (Taxol). https://app.cochat.ai/papers/10.1056/nejm199504133321507
- The paper
- Rowinsky, E. K., & Donehower, R. C. (1995). Paclitaxel (Taxol). New England Journal of Medicine. https://doi.org/10.1056/nejm199504133321507
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.